Annovis Bio Inc.
4.69
0.02 (0.43%)
At close: Jan 15, 2025, 9:40 AM
undefined%
Bid 4.67
Market Cap 64.78M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -4.22
PE Ratio (ttm) -1.11
Forward PE n/a
Analyst Buy
Ask 4.74
Volume 18,164
Avg. Volume (20D) 358,791
Open 4.88
Previous Close 4.67
Day's Range 4.63 - 4.88
52-Week Range 4.21 - 20.00
Beta undefined

About ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for prote...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 29, 2020
Employees 6
Stock Exchange NYSE
Ticker Symbol ANVS

Analyst Forecast

According to 7 analyst ratings, the average rating for ANVS stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 432.49% from the latest price.

Buy 71.43%
Hold 14.29%
Sell 0.00%
Stock Forecasts
2 months ago · Source
-6.25%
Annovis Bio shares are trading lower after the com... Unlock content with Pro Subscription
3 months ago · Source
+14.54%
Annovis Bio shares are trading higher. HC Wainwright & Co. reiterated its Buy rating on the stock.